COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,237 Articles (22,733 medRxiv, 8,504 bioRxiv)

Most recent first Previous |  Page 1017: Articles 10161-10170  | Next

Mapping the antigenic diversification of SARS-CoV-2
van der Straten, K., Guerra, D., van Gils, M., Bontjer, I., Caniels, T. G., van Willigen, H. D., Wynberg, E., Poniman, M., Burger, J. A., Bouhuijs, J. H., Lavell, A., Appelman, B., Sikkens, J. J., Bomers, M., Han, A. X., Nichols, B. E., Prins, M., Vennema, H., Reusken, C., Eggink, D., de Jong, M., de Bree, G. J., Russell, C. A., Sanders, R. W.
10.1101/2022.01.03.21268582 — Posted: 2022-01-03
Melatonin drugs inhibit SARS-CoV-2 entry into the brain and virus-induced damage of cerebral small vessels
Cecon, E., Fernandois, D., Renault, N., Coelho, C. F. F., Wenzel, J., Bedart, C., Izabelle, C., Gallet, S., Le Poder, S., Klonjkowski, B., Schwaninger, M., PREVOT, V., Dam, J., Jockers, R.
10.1101/2021.12.30.474561 — Posted: 2022-01-03
Integrated Autolysis, DNA Hydrolysis and Precipitation Enables an Improved Bioprocess for Q-Griffithsin, a Broad-Spectrum Antiviral and Clinical-Stage anti-COVID-19 Candidate
Decker, J. S., Menacho-Melgar, R., Lynch, M. D.
10.1101/2021.12.30.474602 — Posted: 2022-01-03
Hydrodynamics of spike proteins dictate a transport-affinity competition for SARS-CoV-2 and other enveloped viruses
Moreno, N., Moreno-Chaparro, D., Balboa Usabiaga, F., Ellero, M.
10.1101/2022.01.03.474721 — Posted: 2022-01-03
Cell culture model system utilizing engineered A549 cells to express high levels of ACE2 and TMPRSS2 for investigating SARS-CoV-2 infection and antivirals
Chang, C.-W., Parsi, K. M., Somasundaran, M., Vanderleeden, E., Cruz, J., Cousineau, A., Liu, P., Li, Q., Wang, Y., Maehr, R., Wang, J. P., Finberg, R. W.
10.1101/2021.12.31.474593 — Posted: 2022-01-03
A dual-receptor mechanism between integrins and ACE2 widens SARS-CoV-2 tissue tropism
Nader, D., Gressett, T. E., Hossen, M. L., Chapagain, P. P., Kerrigan, S. W., Bix, G.
10.1101/2022.01.02.474028 — Posted: 2022-01-03 Discussion: Onsite
The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry.
Peacock, T. P., Brown, J. C., Zhou, J., Thakur, N., Newman, J., Kugathasan, R., Sukhova, K., Kaforou, M., Bailey, D., Barclay, W. S.
10.1101/2021.12.31.474653 — Posted: 2022-01-03
In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate
Touret, F., Baronti, C., Bouzidi, H. S., de Lamballerie, X.
10.1101/2022.01.01.474639 — Posted: 2022-01-03
Omicron variant escapes therapeutic mAbs contrary to eight prior main VOC
Boschi, C., Colson, P., Bancod, A., Moal, V., La Scola, B.
10.1101/2022.01.03.474769 — Posted: 2022-01-03
An in vitro and in vivo approach for the isolation of Omicron variant from human clinical specimens
Yadav, P. D., Gupta, N., Potdar, V., Mohandas, S., Sahay, R. R., Sarkale, P., Shete, A. M., Razdan, A., Patil, D. Y., Nyayanit, D. A., Joshi, Y., Patil, S., Majumdar, T., Dighe, H., Malhotra, B., Shastri, J., Abraham, P.
10.1101/2022.01.02.474750 — Posted: 2022-01-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).